References
- Chen Y, Liu L, Laille E, et al. (2010). In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine. Cancer Chemother Pharmacol 65:995–1000
- CHMP. 2012. Guideline on the investigation of drug interactions (EMA). London: CHMP
- Cho YY, Jeong HU, Kim JH, Lee HS. (2014). Effect of honokiol on the induction of drug-metabolizing enzymes in human hepatocytes. Drug Des Dev Ther 8:2137–45
- Costa A, Sarmento B, Seabra V. (2014). An evaluation of the latest in vitro tools for drug metabolism studies. Expert Opin Drug Metab Toxicol 10:103–19
- EMEA. (2016). Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. London: EMEA
- Engelman JA. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550–62
- FDA. (2012). Guidance for industry: drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. Silver Spring, MD: FDA
- FDA. (2014a). Cobimetinib, NDA 206192, Clinical Pharmcology and Biopharmaceutics Review Summary. Silver Spring, MD: FDA
- FDA. (2014b). Olaparib, NDA 206162, Clinical Pharmcology and Biopharmaceutics Review Summary. Silver Spring, MD: FDA
- FDA. (2016). Physiologically based pharmacokinetic analyses – format and content guidance for industry (Draft). Silver Spring, MD: FDA
- Gibbons JJ, Abraham RT, Yu K. (2009). Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 36(Suppl 3):S3–17
- Huang S. (2004). Preliminary Concept Paper Drug interaction studies – study design, data analysis, and implications for dosing and labeling. Silver Spring, MD: US FDA
- Kim DH, Sarbassov DD, Ali SM, et al. (2002). mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163–75
- Madan A, Usuki E, Burton LA, et al. (2002). In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In: Rodrigues AD, ed. Drug–drug interactions. New York: Marcel Dekker, Inc
- Mortensen DS, Fultz KE, Xu S, et al. (2015). CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization. Mol Cancer Ther 14:1295–305
- Ogilvie BW, Zhang D, Li W, et al. (2006). Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191–7
- Parmentier Y, Pothier C, Delmas A, et al. (2017). Direct and quantitative evaluation of the human CYP3A4 contribution (f m) to drug clearance using the in vitro SILENSOMES model. Xenobiotica 47:562–75
- Pearce RE, Mcintyre CJ, Madan A, et al. (1996). Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 331:145–69
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–101
- Tong Z, Atsriku C, Yerramilli U, et al. (2017). Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans. Xenobiotica [Dec 19];[1–11]. [Epub ahead of print]. doi: 10.1080/00498254.2017.1413718
- Tucker GT, Houston JB, Huang SM. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential–toward a consensus. Pharm Res 18:1071–80
- Vivanco I, Sawyers CL. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501
- Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–60
- Zhao P, Ragueneau-Majlessi I, Zhang L, et al. (2009). Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49:351–9